Michael Stewart

2 months ago | modernretina.com | John W. Kitchens |Richard M. Gale |Michael Stewart

January 31, 2025By Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases. Video content above is prompted by the following: What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases? Related Content Related Content

Jan 10, 2025 | modernretina.com | John W. Kitchens |Richard M. Gale |Michael Stewart

Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.

Nov 27, 2024 | medium.com | Michael Stewart

Michael Stewart·Follow12 min read·--The Agile software development process began as a manifesto, a welcome change from the stifling hierarchies and waterfall workflows of traditional project management. It was a revolutionary ethos — prioritizing team collaboration, fast responses to change, early feedback, and the promise of better ways of working. Agile promised liberation — from bureaucratic stagnation, from rigid planning, and from the tyranny of predictability in an unpredictable world.

Nov 25, 2024 | medium.com | Michael Stewart

Michael Stewart·Follow5 min read·--The term “Artificial General Intelligence” (AGI) has long been a source of fascination, speculation, and confusion. It conjures visions of machines capable of thinking, reasoning, and acting like humans across a wide range of tasks. As this current AI hype cycle has accelerated, companies have begun making grand claims about how close they are to this mythical AGI, purporting that achieving it is just around the corner.

May 22, 2024 | fn.bmj.com | Jonathan Davis |Michael Stewart

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.